Recombinant Human Anti-CD44 x Human Anti-CR3 Bispecific Antibody (scFv-CH1/CL) (BSCC-H295)

Recombinant Anti-CD44 x Anti-CR3 Bispecific Antibody (scFv-CH1/CL) is designed to be expressed as two chains. One scFv from an anti-CD44 antibody variable domain is fused to CH1 and the other scFv from an anti-CR3 antibody variable domain fused to CL, or vice versa. And the CH1 and CL domains are linked covalently via a natural disulfide bond. This BsAb can recruit macrophages to tumor cells. It is designed for the research of Glioblastoma; Squamous cancer therapy.

Datasheet

Specifications

Targets

CD44 & CR3

Type

scFv-based Bispecific Fragments

Species Reactivity

Human

Target 1

CD44

Host Animal 1

Mouse

Target 2

CR3

Host Animal 2

Mouse

Application

FuncS; Promising therapeutic agent

Related Disease

Glioblastoma; Squamous cancer

Targets

Target 1

CD44

Gene ID

960

UniProt ID

P16070

Alternative Names

CD44; CD44 antigen; ECMRIII; Extracellular matrix receptor III; HCAM; Homing cell adhesion molecule; Pgp-1; phagocytic glycoprotein-1; HUTCH-1; Ly-24; Pgp-1; HERMES; AU023126; AW121933; AW146109

Target 2

CR3

Gene ID

719

UniProt ID

Q16581

Alternative Names

C3AR1; complement C3a receptor 1; AZ3B; C3AR; HNFAG09; CR3; Complement receptor type 3; CD11b/CD18; Mac-1; Macrophage antigen 1; αmβ2

Our services and products are only for lab research, not for any diagnostic or therapeutic use.

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY

Online Inquiry

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

Europe
Heidenkampsweg 58, 20097 Hamburg, Germany
Tel: 44-207-097-1828
Email: